A Phase IIa, Multicenter, Randomized, Third-Party Unblinded, Adjuvant And Placebo Controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of ACC-001 With QS-21 Adjuvant In Japanese Subjects With Mild To Moderate Alzheimer's Disease .

Trial Profile

A Phase IIa, Multicenter, Randomized, Third-Party Unblinded, Adjuvant And Placebo Controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of ACC-001 With QS-21 Adjuvant In Japanese Subjects With Mild To Moderate Alzheimer's Disease .

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2016

At a glance

  • Drugs QS 21 (Primary) ; Vanutide cridificar (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 18 Jul 2013 Results presented at the 2013 Alzheimer's Association International Conference .
    • 29 Aug 2012 Actual end date (1 Jul 2012) added as reported by ClinicalTrials.gov record.
    • 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top